These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32392114)

  • 21. Splenic large B-cell lymphoma in patients with hepatitis C virus infection.
    Takeshita M; Sakai H; Okamura S; Oshiro Y; Higaki K; Nakashima O; Uike N; Yamamoto I; Kinjo M; Matsubara F
    Hum Pathol; 2005 Aug; 36(8):878-85. PubMed ID: 16112004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma.
    Maurer MJ; Micallef IN; Cerhan JR; Katzmann JA; Link BK; Colgan JP; Habermann TM; Inwards DJ; Markovic SN; Ansell SM; Porrata LF; Johnston PB; Nowakowski GS; Thompson CA; Gupta M; Syrbu SI; Kurtin PJ; Macon WR; Nikcevich DA; Witzig TE
    J Clin Oncol; 2011 Apr; 29(12):1620-6. PubMed ID: 21383282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
    Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.
    Arcaini L; Rossi D; Lucioni M; Nicola M; Bruscaggin A; Fiaccadori V; Riboni R; Ramponi A; Ferretti VV; Cresta S; Casaluci GM; Bonfichi M; Gotti M; Merli M; Maffi A; Arra M; Varettoni M; Rattotti S; Morello L; Guerrera ML; Sciarra R; Gaidano G; Cazzola M; Paulli M
    Haematologica; 2015 Feb; 100(2):246-52. PubMed ID: 25381127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 26. Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature.
    Nooka A; Shenoy PJ; Sinha R; Lonial S; Flowers CR
    Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):379-84. PubMed ID: 21729690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
    Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
    Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low prognostic nutritional index predicts poor outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Zhou Q; Wei Y; Huang F; Wei X; Wei Q; Hao X; Zhang Y; Feng R
    Int J Hematol; 2016 Oct; 104(4):485-90. PubMed ID: 27393279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.
    Rattotti S; Ferretti VV; Rusconi C; Rossi A; Fogazzi S; Baldini L; Pioltelli P; Balzarotti M; Farina L; Ferreri AJM; Laszlo D; Speziale V; Varettoni M; Sciarra R; Morello L; Tedeschi A; Frigeni M; Defrancesco I; Zerbi C; Flospergher E; Nizzoli ME; Morra E; Arcaini L;
    Hematol Oncol; 2019 Apr; 37(2):160-167. PubMed ID: 30726562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy.
    Visco C; Arcaini L; Brusamolino E; Burcheri S; Ambrosetti A; Merli M; Bonoldi E; Chilosi M; Viglio A; Lazzarino M; Pizzolo G; Rodeghiero F
    Ann Oncol; 2006 Sep; 17(9):1434-40. PubMed ID: 16766591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical characteristics of 46 pediatric diffuse large B-cell lymphoma and treatment outcome].
    Huang S; Yang J; Jin L; Duan YL; Zhang M; Zhang NN; Li Q; Zhang N; Zhou CJ; Zhang YH
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):774-779. PubMed ID: 31594064
    [No Abstract]   [Full Text] [Related]  

  • 32. [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
    Guo J; Zhu YP; Gao J; Li Q; Jia CS; Zhou CY; Guo X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):72-9. PubMed ID: 26913397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcome of HCV-positive patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy.
    Salah-Eldin MA; Ebrahim MA; El-Sadda W
    Ann Hematol; 2014 Nov; 93(11):1903-11. PubMed ID: 24951125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma.
    Occhipinti V; Farina L; Viganò M; Capecchi M; Labanca S; Fanetti I; Corradini P; Rumi M
    Dig Liver Dis; 2019 May; 51(5):719-723. PubMed ID: 30502232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clearance of Hepatitis C Virus (HCV) Is Associated With Improved Outcomes in HCV-Associated Lymphoma.
    Desai SH; Baez-Sosa V; Hameed R; Al-Shbool G; Fernandez S; Vakiti A; Stingo F; Adhikari T; Paku E; Malkovska V; Fishbein D
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e185-e193. PubMed ID: 33132102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.
    Cox MC; Pelliccia S; Marcheselli L; Battistini R; Arcari A; Borza PA; Patti C; Casaroli I; di Landro F; Di Napoli A; Fabbri F; Caridi M; Tafuri A; Bocci G; Musuraca G
    Invest New Drugs; 2019 Jun; 37(3):548-558. PubMed ID: 31028663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
    Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
    J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic implications of tumor extent in early-stage diffuse large B-cell lymphoma.
    Yoo C; Yoon DH; Kim JE; Jo J; Park SJ; Yoon SK; Ahn Y; Kim S; Huh J; Lee DH; Suh C
    Int J Hematol; 2013 Feb; 97(2):232-9. PubMed ID: 23359300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients.
    Gouveia GR; Ferreira SC; Siqueira SAC; de Pádua Covas Lage LA; Hallack Neto AE; de Oliveira Costa R; Pereira J
    BMC Cancer; 2020 Oct; 20(1):1041. PubMed ID: 33121489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.